«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2016年第6期

页码:

727-730

栏目:

综述

出版日期:

2016-07-05

文章信息/Info

Title:

Clinical advances in research of fully bioresorbable scaffolds

作者:

纪兆乐; 胡建华; 杨亚丽; 吕 平; 李 妍

(第四军医大学西京医院心血管内科，陕西 西安 710032)

Author(s):

JI Zhao-le;  HU Jian-hua;  YANG Ya-li;  L? Ping;  LI Yan

(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)

关键词:

全吸收式血管支架; 可降解聚合物支架; 经皮冠状动脉介入治疗

Keywords:

fully bioresorbable scaffolds;  biodegradable polymer stents;  percutaneous coronary intervention

分类号:

R618

DOI:

-

文献标识码:

A

摘要:

经皮冠状动脉介入（PCI）治疗已经成为冠心病患者冠脉血运重建的主要手段。第二代金属药物洗脱支架（DES）虽然较以往裸金属支架显著减少了支架内再狭窄和靶病变再次血运重建的发生率，但仍不能从根本上解决支架长期存留带来的问题。新型可吸收支架早期提供血管支撑，随后完全消失，从根本上克服了支架永久存留的不足，成为目前心血管介入领域研究的焦点。本文就目前主要的全吸收式血管支架的种类及相关临床研究进行概述。

Abstract:

Percutaneous coronary intervention (PCI) has become the major method to treat coronary artery diseases (CAD). Second-generation drug-eluting stents (DES) have significantly reduced the occurrence of in-stent restenosis (ISR) and target lesion revascularization (TLR) compared with bare metal stents. However, DES cannot fundamentally resolve the problem caused by permanent mental stents. Fully bioresorbable scaffolds (BRS) are designed to provide temporary support to the vessel walls and subsequently dissolve. BRS have become the focus of current cardiovascular intervention due to the theoretical advantages of the new technology. This article will review the main types of BRS, relevant clinical research and limitations.

参考文献/References

[1]Stone GW,Ellis SG,Cox DA,et al.A polymer-based,paclitaxel eluting stent in patients with coronary artery disease[J].N Engl J Med,2004,350(3):221-231.
[2]Serruys PW,Omuna Y,Garg S,et al.5-year clinical outcomes of the ARTS II(Arterial Revascularization Therapies Study II)of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions[J].J Am Coll Cardiol,2010,55(11):1093-1101.
[3]Brugaletta S,Heo JH,Garcia-Garcia HM,et al.Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer:indirect finding of vascular reparative therapy?[J].Eur Heart J,2012,33(11):1325-1333.
[4]Campos CM,Muramatsu T,Iqbal J,et al.Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery diseas[J].Int J Mol Sci,2013,14(12):24492-24500.
[5]Ghimire G,Spiro J,Kharbanda R,et al.Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents[J].Eurolntervention,2009,4(4):481-484.
[6]Haude M,Erbel R,Eme P,et al.Safety and performance of the drug-eluting absorbable metal scaffold(DREAMS)in patients with de-novo coronary lesions:12 month results of the prospective,multicentre,first-in-man BIOSOLVE-I trial[J].Lancet,2013,381(9869):836-844.
[7]Haude M,Ince H,Abizaid A,et al.Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions(BIOSOLVE-II):6 month results of a prospective, multicentre, non-randomised,first-in-man trial[J].Lancet,2016,387(10013):31-39.
[8]Waksman R,Pakala R,Baffour R,et al.Short-term efects of biocorrodible iron stents in porcine coronary arteries[J].J Interv Cardiol,2008,21(1):l5-20.
[9]Tamai H,Igaki K,Kyo E,et al.Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans[J].Circulation,2000,102(4):399-404.
[10]Nishio S,Kosuga K,Igaki K,et al.Long-Term(>10 Years)clinical outcomes of first-in-human biodegradable poly-l-lactic acid coronary stents:Igaki-Tamai stents[J]. Circulation,2012,125(19):2343-2353.
[11]Biamino G,Schmidt A,Scheinert D,et al.Treatment of SFA lesions with PLLA biodegradable stents:results ofthe PERSEUS study[J].J Endovasc Ther,2005,12(Suppl 1):115-120.
[12]Werner M,Micari A,Cioppa A,et al.Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery:the GAIA study[J].JACC Cardiovasc Interv,2014, 7(3):305-312.
[13]Ormiston JA,Serruy PW,Regar E,et al.A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions(ABSORB):a prospective open-label trial[J].Lancet, 2008,371(9616):899-907.
[14]Dudek D,Omuna Y,Ormiston JA,et al.Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease:the ABSORB trial[J].EuroIntervention,2012,7(9):1060-1061.
[15]Ormiston JA,Serruys PW,Omuna Y,et al.First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold:a multi-imaging modality study[J].Circ Cardiovasc Interv,2012,5(5):620-632.
[16]Serruys PW,Chevalier B,Dudek D,et al.A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions(ABSORB II):an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial[J].Lancet,2015,385(9962):43-54.
[17]Ellis SG,Kereiakes DJ,Metzger DC,et al.Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease[J].N Engl J Med,2015,373(20):1905-1915.
[18]Gao R,Yang Y,Han Y,et al.Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients with Coronary Artery Disease:ABSORB China trial[J].J Am Coll Cardiol,2015,66(21):2298-2309.
[19]Diletti R,Karanasos A,Muramatsu T,et al.Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study[J].Eur Heart J,2014,35(12):777-786.
[20]Dudek D,Rzeszutko L,Zasada W,et al.Bioresorbable vascular scaffolds in patients with acute coronary syndromes:the POLAR ACS study[J].Pol Arch Med Wewn,2014,124(12):669-677.
[21]Kocka V,Maly M,Tousek P,et al.Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction:a prospective multicentre study 'Prague 19'[J].Eur Heart J,2014,35(12):787-794.
[22]Capodanno D,Gori T,Nef H,et al.Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice:early and midterm outcomes from the European multicentre GHOST-EU registry[J].EuroIntervention,2015,10(10):1144-1153.
[23]Cassese S,Byme RA,Ndrepepa G,et al.Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents:a meta-analysis of randomised controlled trials[J].Lancet,2016,387(10018):537-544.
[24]Costa JR,Abizaid A, Feres F,et al.EXCELLA First-in-Man(FIM)study: safety and efficacy of novolimus eluting stent inde novo coronary lesions[J]. Eurolntervention,2008,4(1):53-58.
[25]Wu Y,Shen L,Wang Q,et al.Comparison of acute recoil between bioabsorbable poly-L-lactic acid XINSORB stent and metallic stent in porcine model[J].J Biomed Biotechnol,2012,2012:413956.
[26]Chen JH,Wu YZ,Shen L,et al.First-in-man Implantation of the XINSORB Bioresorbable Sirolimus-eluting Scaffold in China[J].Chin Med J(Engl),2015,128(9):1275-1276.
[27]Muramatsu T,Onuma Y,Garcia-Garcia HM,et al.Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold:an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials[J].JACC Cardiovasc Interv,2013,6(3):247-257.

备注/Memo

备注/Memo:

收稿日期：2016-01-24.
通讯作者：李妍，副教授，主要从事冠心病诊疗及介入研究 Email:liyanfmmu@hotmail.com
作者简介：纪兆乐，硕士生Email:1814701299@qq.com

常用功能

更新日期/Last Update: 2016-07-10